Jennifer Kyle

CEO and Founder

Condor

Feb 2020 - Current (6 years 5 months)

Financial intelligence platform, purpose built for biopharma and life sciences. Every dollar fuels innovation. Every decision drives impact. Every breakthrough happens faster.

Founder & CEO

Condor

Feb 2020 - Current (6 years 5 months)

Financial intelligence platform, purpose built for biopharma and life sciences. Every dollar fuels innovation. Every decision drives impact. Every breakthrough happens faster.

J

Biopharma Finance Consultant

JDK Consulting Advisory

Jan 2018 - Jul 2021 (3 years 7 months)

Helped biotech finance teams succeed and grow. Finance consultant for several private and public biotech companies ranging from preclinical to commercial stage, improving mission critical workflows with automation, analytics and SOX compliance to their R&D programs.

Senior Director, Finance and Corporate Controller

Gerrity

Mar 2017 - Jan 2018 (11 months)

Recruited to establish and improve company’s finance and treasury functions. Served on Investment Committee and participated in strategic analysis and decision making for acquisitions.

Director of Finance and Operations

Pirch

Mar 2016 - Mar 2017 (1 year 1 month)

Hired by the CFO to prepare company for IPO. As a result of subsequent investor-led restructuring, including replacement of the entire C-Suite, I elevated to lead the finance function for distribution and logistics operations encompassing 250+ employees over 7 national distribution sites.

Audit

EY

Jul 2014 - Mar 2016 (1 year 9 months)

Big 4 public accounting firm and leading firm for life sciences. • Performance rated in the top 10% within the West Region of EY, and trusted by leadership as a go-to professional for higher risk/complex clients • Selected by partners to lead high visibility IPOs from initial engagement through SEC filings • Led and supervised audit teams for clients ranging from large-cap public companies to private funds and companies, focused in life sciences, biotech and real estate. • Experienced in SEC reporting, project management, and Sarbanes-Oxley 404

Assurance Senior

EY

Jul 2014 - Mar 2016 (1 year 9 months)

Big 4 public accounting firm and leading firm for life sciences. • Performance rated in the top 10% within the West Region of EY, and trusted by leadership as a go-to professional for higher risk/complex clients • Selected by partners to lead high visibility IPO from initial engagement through SEC filing; subsequently acquired in IPO pre-empt for $1 Billion. • Led and supervised audit teams for clients ranging from large public companies ($6B market cap) to private funds and companies, focused in life sciences, biotech and real estate. • Experienced in SEC reporting, project management, and Sarbanes-Oxley 404

Audit

Lavine Lofgren Morris Engelberg LLP

Sep 2012 - Jun 2014 (1 year 10 months)

Audit Associate

Lavine Lofgren Morris Engelberg LLP

Sep 2012 - Jun 2014 (1 year 10 months)

About

Detail

Timeline

Résumé